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Abstract—There is strong evidence that vascular risk factors
play a role in the development of Alzheimer’s disease (AD) or
vascular dementia (vaD). Ethanol (EtOH) and cholesterol are
such vascular risk factors, and we recently showed that hy-
percholesterolemia causes pathologies similar to AD [Ullrich
et al. (2010) Mol Cell Neurosci 45, 408–417]. The aim of this
study was to investigate the effects of long-term (12 months)
EtOH treatment (20% v/v in drinking water) alone or long-term
5% cholesterol diet alone or a combination (mix) in adult
Sprague–Dawley rats. Long-term EtOH treatment (plasma
EtOH levels 5823 mg/dl) caused significant impairment of
spatial memory, reduced the number of choline acetyltrans-
ferase- and p75 neurotrophin receptor-positive nucleus basa-
lis of Meynert neurons, decreased cortical acetylcholine, el-
evated cortical monocyte chemoattractant protein-1 and tis-
sue-type plasminogen activator, enhanced microglia, and
markedly induced anti-rat immunoglobulin G-positive blood–
brain barrier leakage. The effect of long-term hypercholester-
olemia was similar. Combined long-term treatment of rats
with 20% EtOH and 5% cholesterol (mix) did not potentiate
treatment with EtOH alone, but instead counteracted some of
the EtOH-associated effects. In conclusion, our data show
that vascular risk factors EtOH and cholesterol play a role in
cognitive impairment and possibly vaD. © 2012 IBRO. Pub-
lished by Elsevier Ltd. All rights reserved.
Key words: cholinergic dysfunction, ethanol, blood–brain
barrier leakage, cognitive decline.
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly people. The hallmark pathologies
include beta-amyloid (A) depositions in brain (plaques)
nd vessels (amyloid angiopathy), tau pathology, cerebro-
ascular dysfunction, cholinergic impairment, microglia ac-
ivation, and inflammation. The causes of AD are unknown,
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, interleukin 1-; MIP-2, macrophage inflammatory protein-2; nbM,
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Open access under CC BY-NC-NDut cerebrovascular damage may play a key role in its
evelopment (Bell and Zlokovic, 2009; Deane and Zlok-
vic, 2007; Iadecola, 2004; Humpel, 2011). Ethanol
EtOH) is such a vascular risk factor (Monforte et al., 1990;
illbom and Kaste, 1981) and heavy EtOH consumption
eads to neurodegenerative impairment as indicated by the
oss of cortical and subcortical brain structures, as well as
ncreased ventricular volumes (Crews and Nixon, 2009;
harness, 1993). These findings may be caused by cere-
rovascular abnormalities, accompanied by the influx of
oxic substances into the brain and an impaired clearance
t the blood–brain barrier (BBB). To date there is no
vidence that EtOH could be involved in the development
f AD. Although some studies reported that EtOH may
lter amyloid precursor protein (APP) and APP-processing
nzymes (Kim et al., 2011), may cause neuritic plaques in
ats (Paula-Barbosa and Tavares, 1984), may increase
evels of hyperphosphorylated tau (Sun et al., 2005), and
ay favor A production (Lahiri et al., 2002), a direct
orrelation between AD and EtOH consumption has not
een found (Graves et al., 1990; Rosen et al., 1993;
anaka et al., 2002; Aho et al., 2009). Several studies
uggest a protective effect of moderate chronic EtOH on
D development (Anstey et al., 2009; Tyas, 1996). In fact,
tOH has a cholesterol-reducing effect on the cardiovas-
ular system and a protective effect against AD, whose
athology has been limited to altered cholesterol hemosta-
is in the brain (Guizzetti and Costa, 2007).
However, there is clear evidence that EtOH consump-
ion causes cognitive decline and cholinergic dysfunction,
ymptoms also found in AD and vascular dementia (vaD)
Floyd et al., 1997; Arendt, 1994; Arendt et al., 1995). In
act, the cholinergic system seems to be particularly sen-
itive to EtOH-induced degeneration (Floyd et al., 1997;
rendt, 1994; Arendt et al., 1995), and chronic EtOH re-
ulted in a degeneration of cholinergic neurons in the basal
orebrain (Arendt, 1994), decreased levels of acetylcholine
ACh), choline acetyltransferase (ChAT), and acetylcho-
ine esterase (AChE) in the basal nucleus of Meynert
nbM) in rats (Arendt et al., 1988), accompanied by in-
reased cortical nerve growth factor (NGF) levels (Arendt
t al., 1995). NGF supports the survival of cholinergic
eurons (Humpel and Weis, 2002), and accumulation in
ortical cholinergic projection areas may be caused by the
mpairment of retrograde transport mechanisms (Salehi et
l., 2007; Scott et al., 1995; Mufson et al., 1995).
The aim of the present study was to investigate the
ffects of long-term (12 months) moderate EtOH treatment
n male Sprague–Dawley rats on (1) spatial memory, (2)
 license.
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166 155cholinergic neurons, (3) inflammation, and (4) the vascular
system. As we previously showed that the vascular risk
factor cholesterol markedly affected all four mentioned
functions after short-term (5 months) treatment (Ullrich et
al., 2010), we now wanted to compare the effects of long-
term (12 months) EtOH and cholesterol treatment. Finally,
we were interested in investigating whether some of these
markers induced by hypercholesterolemia are affected by
EtOH co-treatments (mix). These experiments may bring
some insights into the mechanisms how long-term vascu-
lar risk factors may contribute to cognitive impairment.
EXPERIMENTAL PROCEDURES
Animals
Adult male Sprague–Dawley rats were housed at the Animal
Department of Innsbruck Medical University with free access to
food and water and a 12/12 h light–dark cycle. Animals were
randomly divided into four groups: (1) control group: tap water and
normal food (n12), (2) EtOH group: 20% EtOH (Gatt-Koller,
Austria) as the sole drinking fluid and normal food (n12), (3)
cholesterol group: tap water and a diet supplemented with 5%
cholesterol (n12) (see Ullrich et al., 2010), (4) mixed group: 20%
EtOH as the sole drinking fluid and a diet supplemented with 5%
cholesterol (n12) (see Ullrich et al., 2010). The EtOH concen-
tration was initially 5% and was progressively increased by 5% per
week until a final concentration of 20% (v/v) was achieved 4
weeks later. All animals were treated for 12 months as well as
during the testing period and were weighed before and at the end
of the experiment. All animal experiments were approved by the
Austrian Ministry of Science. All attempts were done to minimize
the number of animals and their suffering.
Spatial memory testing in the eight-arm radial maze
Spatial memory was assessed using the eight-arm radial maze
(PanLab, Spain), as described in detail (Pirchl et al., 2010; Ullrich
et al., 2010). Eleven months after starting the experiment spatial
learning and long-term memory performance were assessed. The
maze consists of eight identical open, dark Plexiglas® arms with
side panels and recessed cups at the outer end radiating from a
circular platform. To facilitate spatial navigation, small high-con-
trast visual cues (triangle, vertical bars, cross and square) were
placed above the doors of four arms and in a higher magnification
on the corresponding walls. Two days before the experiment food
deprivation commenced (2 g food pellets administered per animal
per day), however, animals had free access to water and ethanol
exposure was continued. Animals were then habituated to the
maze for 1 day (four trials of 10 min each). Three days after
habituation the actual spatial learning test commenced, which
consisted of five trials per day (session) on five consecutive days.
For each trial four arms were baited with food pellets (chocolate
cereals), and the trial ended when all baits were found or after 10
min had elapsed. To exclude any olfactory effects additional baits
were placed under the food cup in each arm and the maze was
cleaned with 70% ethanol after every trial. Thereafter, the ses-
sions and food deprivation were discontinued for 19 days, namely
2 days before the retention session, when food deprivation was
resumed. The animals were again tested for one session (con-
sisting of five trials) to assess spatial long-term memory perfor-
mance (retention). Memory errors were quantified according to
Jarrard’s definition (Jarrard et al., 1984). Working memory errors
(WME) were defined as repeat visits to baited arms. The first visit
to an unbaited arm was defined as a reference memory error
(RME), and the combination of both errors, namely repeat visits to
unbaited arms, was specified as a working-reference memoryerror (WRME). The whole experiment was automatically con-
trolled and monitored by a computer with Mazesoft Software
(version 8.1.9).
Collection of blood and brains
One day after the last retention, animals were anesthetized with a
subcutaneous injection of sodium thiopental (12.5 mg/ml; Sandoz,
Austria). Blood was drawn directly from the heart using a 21-gauge
butterfly blood collection system (BD Valu-Set, BD, UK) and col-
lected in ethylenediaminetetraacetic acid tubes (S-monovettes,
Sarstedt, Germany). Blood was centrifuged at 250g for 15 min to
obtain plasma, further centrifuged twice at 2300g for 10 min to
remove remaining platelets, and finally stored at 80 °C. For brain
extracts, the brains (n6 per group) were removed, the frontal cortex
issected (left and right hemispheres separate in a tube) and imme-
iately frozen in CO2 snow and stored at80 °C until further use. For
mmunohistochemistry, rats were perfused with 4% paraformalde-
yde (PFA, Merck, Germany) in phosphate-buffered saline (PBS),
rains were removed and postfixed for 30 min in 4% PFA and stored
n 20% sucrose/sodium azide. Brains were frozen under CO2 snow
nd sliced into 60-msections with a cryostate (Leica Jung CM3000,
Germany).
Measurement of EtOH in plasma and cortex
Cortex tissue (left hemisphere) was homogenized in 100 l ice-
cold PBS with a protease-inhibitor cocktail (Sigma, Germany)
using an ultrasonic device (Branson Sonifier 250, Danbury, USA)
and centrifuged at 16,000g for 10 min at 4 °C. EtOH levels in
cortex extracts and plasma were measured using an EnzyChromTM
EtOH Assay Kit Ecet-100 (BioAssay Systems, Hayward, CA, USA).
Measurement of cholesterol in plasma
Cholesterol was analyzed by high-performance liquid chromatog-
raphy (HPLC) and UV detection as described by Webb et al.
(1982) and reported recently by us (Ullrich et al., 2010). Briefly, 50
l of plasma or standards (0–5 mg/ml cholesterol in 70% chloro-
orm) were mixed with 1 ml of alcoholic potassium hydroxide and
ncubated for 30 min at 75 °C. After cooling to room temperature,
ml of de-ionized water and 2 ml of n-hexane were added to the
ubes. The tubes were agitated for 15 min and centrifuged for 5
in at 200g. One ml of the n-hexane (upper) layer was trans-
erred to a glass tube and evaporated at 75 °C. Residues were
issolved in 500 l mobile phase (44% acetonitrile, 54% isopro-
anol, 2% a.d.) and 100 l was injected onto the column (reversed
phase C18 1003 mm, Shimadzu, Kyoto, Japan) at a flow rate of
0.6 ml/min. Cholesterol was monitored at 205 nm with a UV
detector (Antec-Leyden Decade II, Zoeterwoude, Netherlands).
Sample values were calculated from the standard curve in a linear
range.
Measurement of ACh in the cortex
ACh levels were analyzed by HPLC and electrochemical detection
as described by us (Ullrich et al., 2010; Pirchl et al., 2010). Briefly,
the tissue (right hemisphere) was homogenized in 150-l ice-cold
PBS (5 M neostigmine, pH 5.3, Sigma, Austria) using an
ltrasonic device (Branson Sonifier 250, Danbury, USA) and cen-
rifuged at 16,000g for 5 min at 4 °C. The supernatant (100 l)
as rapidly injected onto the analytical column (BASI MF6150,
arwickshire, UK) connected to an “immobilized enzyme reactor”
BASI MF6151, Warwickshire, UK). This reactor hydrolyzes ACh
nd generates hydrogen peroxide (H2O2), which is electrochem-
ically detected through oxidation (500 mV vs. Ag/AgCl2) using
an electrochemical detector (Antec-Leyden Decade II, Zoeter-
woude, Netherlands). The mobile phase included 50 mM sodium
phosphate and 0.01% sodium azide, pH 8.5. The amount of ACh
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166156in the homogenates was quantified using calibration curves for
external ACh standards (Sigma, Germany).
Immunohistochemistry
Immunohistochemistry using the avidin-biotin technique was per-
formed as described previously (Pirchl et al., 2010; Ullrich et al.,
2010). All incubations were performed at 4 °C over 2 days includ-
ing 0.1% Triton (Merck, Germany). Fixed sections (n6) were
rinsed for 30 min with 0.1% Triton/PBS (T-PBS) at room temper-
ature and pretreated for 20 min with 20%methanol/1% H2O2/PBS.
Subsequently, the slices were washed three times for 10 min with
PBS, blocked with 20% horse serum/0.2% BSA/T-PBS and incu-
bated with the primary antibody against goat anti-choline acetyl-
transferase (1:750, Chemicon, USA), anti-p75 neurotrophin re-
ceptor (p75NTR, 1:1000, Promega Madison, WI, USA) mouse
anti-laminin (1:500 Sigma, UK), mouse anti-RECA-1(1:100 Sero-
tec, Kidlington, UK), mouse anti-CD11b (1:500 Millipore, Billerica,
USA), rabbit anti-ionized calcium-binding adapter molecule 1
(Iba-1, 1:500, Wako, Wako, Germany) in 0.2% BSA/T-PBS for 2
days at 4 °C. Slices were washed and incubated with secondary
biotinylated anti-goat, anti-mouse, or anti-rabbit antibody (1:200,
Vector Laboratories, Burlingame, CA, USA) for 1 h at room tem-
perature. After rinsing three times in PBS, slices were incubated in
avidin-biotin complex solution (ABC; Elite Standard PK 6100,
Vector Laboratories, Burlingame, CA, USA) for 1 h and subse-
quently washed three times in 50 mM Tris-buffered saline (TBS).
The signal was detected using 0.5 mg/ml 3,3= diaminobenzidine
(DAB) in TBS with 0.003% H2O2 as substrate. Slices were then
rinsed in PBS and mounted on glass slides.
Evaluation of BBB disruption
Impairment of BBB was assessed using immunohistochemistry for
rat immunoglobulin G (IgG) as described by us (Pirchl et al., 2010;
Ullrich et al., 2010). Sections were incubated in biotinylated rabbit
anti-rat IgG (1:400 Vector Laboratories, USA) for 2 h. After rinsing
they were incubated in an avidin-biotin complex solution (ABC-
Elite Vectastain reagent, Vector Laboratories, USA) for 1 h. Visu-
alization was performed identically as described for immunohisto-
chemistry.
Enzyme-linked immunosorbent assay (ELISA)
measurements for NGF, inflammatory markers, tPA,
and beta-amyloid
Cortical extracts from both hemispheres were used. NGF analysis
was performed with a commercial ELISA kit (Promega, Madison,
WI, USA) as previously described in detail (Pirchl et al., 2010;
Ullrich et al., 2010). Inflammatory markers were analyzed using a
Multiplex rat ELISA (SearchLight®, Aushon Biosystems, USA) as
previously described in detail (Pirchl et al., 2010; Ullrich et al.,
2010). Tissue-plasminogen activator (tPA) was measured with a
commercial ELISA kit (Oxford Biochemical Research, PA 94,
USA). ELISA measurements of rat A(1-40) and A(1–42) were
performed with commercial highly sensitive ELISA kits (294-
64701 and 292-64501, Wako, Germany) as previously described
(Marksteiner and Humpel, 2008).
Quantitative analysis and statistics
Behavioral testing was statistically analyzed within groups using a
one-way repeated measures analysis of variance (ANOVA)
(S1–S5 and S5-Ret) and between control and EtOH- and choles-
terol-fed animals using Student’s t-test and the F-test to compare
or equal variance. The number of ChAT- or p75NTR-positive neu-
ons was counted in the nbM between bregma0.7 mm and3.1
m in control and EtOH-treated as well as in EtOH- and choles-erol-fed rats visualized under a 20 objective, according to the *at brain atlas (Paxinos and Watson, 1986), by an investigator
linded to the treatment code. Rat anti-IgG-positive spots (as a
arker for BBB leakage) were counted in the cortex in six fields
er section and in four sections per brain under a 20 objective in
ll groups. Sections were photographed under the microscope
nd digitized pictures overlaid in NIH ImageJ software with a grid
150150 m2 per square). The capillary network in the cortex
was assessed, as described by us in detail (Pirchl et al., 2010;
Ullrich et al., 2010), by counting the number of crossings of
RECA-1- or laminin-positive capillaries across the lines of the
overlaid grid. Quantitative data are presented as mean
valuesSEM. The significance of differences between the control
and the EtOH or mixed group was assessed with the one-way
ANOVA, followed by the Fisher PLSD post hoc test by comparing
controls with the EtOH or the mixed EtOH and cholesterol group
or with Student’s t-test, where P0.05 represents statistical sig-
nificance.
RESULTS
Effect of EtOH treatment on plasma levels and
weight
When rats were treated with 20% EtOH for 12 months, the
plasma EtOH levels were seen to be significantly in-
creased in the EtOH group as compared with controls
(Table 1). No EtOH levels were detectable in the cortex of
either group. The weight of the EtOH-treated rats (58016
g, n6) was significantly decreased after 12 months as
compared with that of the control animals (65223 g, n6;
Fig. 1A). The plasma levels of tPA, A, and several inflam-
matory markers were not affected by EtOH (Table 1).
EtOH affects spatial memory
Spatial memory was tested in an eight-arm partially baited
maze. Rats treated with EtOH showed a markedly im-
Table 1. Analysis of plasma markers after long-term (12 mon) ethanol
(EtOH) treatment
Plasma Control EtOH
EtOH [mM‰mg/dl] below DL 12.5  5.20.7  0.3
57.7  23.3*
Cholesterol [mg/ml] 0.7  0.1 0.5  0.1 ns
tPA [ng/ml] 10.9  1.4 13.7  3.0 ns
A(1–40) [pM] 38.7  5.9 37.6  8.9 ns
A(1–42) [pM] 3.7  0.3 4.8  0.8 ns
IL-1 [pg/ml] 9.7  7.7 10.1  4.0 ns
IP-2 [pg/ml] 3.8  1.7 4.8  2.7 ns
NF- [pg/ml] 29.3  19.5 19.4  13.0 ns
CP-1 [ng/ml] 3.6  0.5 3.0  0.3 ns
Sprague–Dawley rats were administered normal water (controls) or
20% EtOH-enriched water for 12 mon. Blood was collected and
plasma samples were analyzed with the ethanol detection kit for EtOH
levels, cholesterol by HPLC-UV detection, and ELISAs for interleukin
1-beta (IL-1), monocyte chemotactic protein-1 (MCP-1), macrophage
nflammatory protein-2 (MIP-2), tumor necrosis factor-alpha (TNF-),
issue plasminogen activator (tPA), beta amyloid(1–40) (A(1–40)), beta-
amyloid(1–42) (A(1–42)). Values are given as meanSEM in [pg/ml,
g/ml, pM, mg/dl, or %]. Statistical analysis was performed with a
ne-way ANOVA with a Fisher LSD post hoc test (n6 animals per
roup; tPA, n3). ns, not significant; below DL, below detection limit,
P0.001.
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166 157paired performance in the learning tasks in sessions 3 and
5 (Fig. 1B) and in retention after 3 weeks (Fig. 1B). WME,
ME, and WRME were markedly enhanced in EtOH-
reated rats as compared with controls (Fig. 1C). EtOH-
reated animals did not show any difference in the time
eeded to find all baits or in the length of time spent in the
isited arms (Fig. 1D). However, the number of total visits
as markedly increased in EtOH-treated rats (Fig. 1D).
tOH decreases cholinergic activity in the nbM
holinergic neurons in the nbM were immunohisto-
hemically stained for the ACh synthesizing enzyme
hAT (Fig. 2A, C, D) and p75 neurotrophin receptor
p75NTR; Fig. 2E). ChAT- (Fig. 2B) and NGF receptor
p75NTR-positive (Fig. 2F) neurons were evaluated within
the bregma area 0.7 to 3.1 mm. The number of ChAT-
positive neurons in EtOH-treated rats was significantly
decreased as compared with controls (Fig. 2B). EtOH treat-
ment revealed a significant decline in p75NTR-positive neu-
ons (Fig. 2F). The neurotransmitter ACh levels in the cortex
Fig. 1. Effects of long-term (12 months) ethanol (EtOH) treatment in m
significantly decreased in EtOH-treated animals as compared with co
decline in spatial memory performance (sessions 3 and 5), which was c
squares). (C) EtOH-treated animals showed enhanced WME, RME as
rats, no change was seen in the time needed to find all four baits or the
Values in parenthesis give the number of rats. Statistical analysis wa
ignificant.ere markedly reduced in EtOH-treated rats (Table 2).ffects of EtOH on cortical markers
ortical levels of NGF (the most potent cholinergic neuro-
rotective marker) showed no difference between EtOH-
reated rats and controls (Table 2). ELISA measurements
f A(1–40) and A(1–42) (the peptides that aggregate in
D) revealed no differences between EtOH-treated rats
nd controls (Table 2). EtOH did not affect the inflamma-
ory cytokines interleukin 1- (IL-1) and tumor necrosis
factor-alpha (TNF-) or the chemokine macrophage in-
flammatory protein-2 (MIP-2) in the cortex (Table 2). How-
ever, MCP-1 (another inflammatory marker) and tPA (a
general marker of degeneration) levels in the cortex were
significantly increased in EtOH-treated animals (Table 2).
EtOH induces cortical BBB leakage and microglia
activation
BBB leakage in the cortex was identified by immunohisto-
chemistry against rat IgG in controls (Fig. 3A) and EtOH-
treated animals (Fig. 3B, C). Quantitative analysis re-
ague–Dawley rats on weight and spatial memory. (A) Rat weight was
) After 12 mon EtOH-treated rats (filled cycles) exhibited a significant
tly declined after 3 wk (retention, Ret) as compared with controls (open
RME. (D) Although the number of total visits was enhanced in EtOH
f time spent in the visited arm. Values are expressed as meanSEM.
med with Student’s t-test. *** P0.001; ** P0.01; * P0.5; ns, notale Spr
ntrols. (B
onsisten
well as W
length ovealed a markedly increased number of IgG spots in the
c
a
D. Ehrlich et al. / Neuroscience 205 (2012) 154–166158Fig. 2. Effects of long-term (12 months) ethanol (EtOH) treatment on cholinergic neurons in the brain. (A) The number of choline-acetyltransferase
(ChAT)-positive neurons in the basal nucleus of Meynert was counted between bregma0.8 mm and3.1 mm (B) and revealed a decreased number
of ChAT-positive neurons in EtOH-fed rats (open squares, D) as compared with control animals (filled cycles, C). Small boxes show a magnification
of ChAT- and p75NTR-positive neurons. EtOH-treated rats exhibited a decreased number of p75NTR-positive neurons in the nbM (F) as compared with
ontrols (E). Statistical analysis was performed with a one-way ANOVA with a Fisher LSD post hoc test. * P0.05. Scale bar in A2800 m (C, D)
nd 150 m (E) and 20 m (small boxes).
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166 159EtOH group as compared with controls (Fig. 3D). Microglia
in cortex were stained for Iba-1 (Fig. 4A) and OX-42 (both
of which label resting or activated microglia) (Fig. 4D) in
controls (Fig. 4A, D) and EtOH-treated animals (Fig. 4B,
E). Quantitative analysis showed a significantly enhanced
optical density of Iba-1 immunoreactivity after EtOH treat-
ment (Fig. 4C), whereas no changes in OX-42 density
were detectable (Fig. 4F). Vascular structures in the
cortex were stained for RECA-1 (Fig. 5A) and laminin
(Fig. 5B), but no differences in the number of crossings
per grid or in the optical density were seen after EtOH
treatment (Fig. 5C).
Effects of cholesterol (12 months)
The cholesterol group showed significantly increased
weight as compared with the other groups (Table 3);
plasma cholesterol levels (1.50.2 mg/ml) and plasma tPA
levels were also elevated (Table 3). Spatial memory was
impaired and performance by cholesterol-fed animals was
poorer in session 5 and on retention in the maze (Table 3).
Cortical IgG-positive spots and A(1–40) content were sig-
ificantly increased (Table 3). MCP-1, but no other inflam-
atory marker, was enhanced by the cholesterol treat-
ent. The optical density of the vascular and extracellular
atrix marker laminin was decreased, but the number of
rossings of laminin-positive capillaries was increased (Ta-
le 3). The number of cholinergic neurons in the nbM was
ecreased as compared with controls (Table 3).
ffects of combined EtOH and hypercholesterolemia
hen comparing combined EtOH and cholesterol treat-
Table 2. Analysis of cortical markers after long-term (12 mon) ethanol
(EtOH) treatment
Cortex Control EtOH
EtOH [mM] below DL below DL
ACh [ng/mg] 10.9  2.3 5.1  1.3*
NGF [pg/mg] 46.9  3.2 48.8  2.8 ns
tPA [ng/mg] 0.68  0.06 1.08  0.07**
A(1–40) [pM] 37.1  2.6 39.5  4.6 ns
A(1–42) [pM] 4.8  0.1 4.7  0.6 ns
L-1 [pg/mg] 2.5  0.2 3.1  0.4 ns
IP-2 [pg/mg] 1.2  0.3 1.3  0.3 ns
NF- [pg/mg] 2.6  0.4 2.1  0.3 ns
CP-1[pg/mg] 16.5  1.2 23.8  3.7*
Sprague–Dawley rats were administered normal water (control) or
0% EtOH-enriched water for 12 mon. Brains were removed and
ortex extracts were analyzed with ELISAs for interleukin 1-beta (IL-
), monocyte chemotactic protein-1 (MCP-1), macrophage inflamma-
tory protein-2 (MIP-2), tumor necrosis factor-alpha (TNF), tissue
lasminogen activator (tPA), A(1–40), A(1–42), and nerve growth fac-
or (NGF). EtOH levels were measured with an ethanol detection kit.
cetylcholine (ACh) levels were assessed by means of HPLC and
lectrochemical detection. Values are given as meanSEM in [pM,
M, pg/mg tissue, or ng/mg tissue]. The number of animals per group,
6; tPA, n3; Statistical analysis was performed with a one-way
NOVA with a Fisher LSD post hoc test. **P0.001; *P0.05; ns, not
ignificant; below DL, below detection limit.ent (mix) with EtOH-only treatment plasma EtOH levelsere significantly decreased, A(1–40) content markedly
eclined, and RECA-1 optical density significantly in-
reased, whereas all other measured parameters were not
ffected (Table 3). When comparing combined EtOH and
holesterol treatment (mix) with cholesterol-only treatment
he animal weight was significantly decreased, the RME
nd RWME were significantly increased, and visits to the
aze were significantly increased, plasma EtOH levels
ere enhanced, plasma cholesterol levels were de-
reased, cortical A(1–40) and A(1–42) content was de-
reased and RECA-1 optical density was increased. Al-
hough laminin-positive crossings were decreased, no
ther measured parameters were affected (Table 3).
DISCUSSION
The present study shows that long-term (12 months) EtOH
treatment (similar to hypercholesterolemia) induced spatial
learning impairment, a decline in cholinergic nbM neurons,
cortical BBB leakage, and partly increased inflammation.
Combined treatment with EtOH and cholesterol did not
potentiate the EtOH-induced effects, but instead EtOH
partly counteracted the cholesterol-associated effects.
EtOH consumption has emerged as an important risk
factor for cerebrovascular diseases, such as stroke (Mon-
forte et al., 1990; Hillbom and Kaste, 1981) or vascular
dementia (Mostofsky et al., 2010), whereas there is in-
creasing evidence that chronic EtOH does not affect de-
velopment of AD, but instead is protective. EtOH readily
passes the BBB. Thus, brain and blood levels rapidly
equilibrate after EtOH consumption (Diamond and Mess-
ing, 1994). Intoxication in non-alcoholics starts at 50–150
mg/dl (Goldstein et al., 1983) and levels of 500 mg/dl can
be fatal for non-drinkers (Diamond and Messing, 1994). In
the present study we administered 20% EtOH in drinking
water to rats, resulting in plasma EtOH levels of 57.723.3
mg/dl, which is in line with others (Arendt et al., 1995) and
correlates with low to moderate EtOH consumption in hu-
mans. Body weight was markedly decreased in EtOH-
treated animals, which most likely results from the malnu-
tritive effect of EtOH, which may also play a role in neuro-
degeneration and cognitive decline (Mendenhall et al.,
1993; Zahr et al., 2011). In EtOH research isocaloric diet or
pair feeding is commonly used to eliminate effects owing to
reduced food intake during EtOH treatment. This treatment
has not been performed in the present study due to long-
term treatment over 12 months, thus we cannot exclude
that some of the effects (e.g. weight reduction) may occur
because of reduced food or liquid uptake rather than to the
EtOH-exposure.
Evaluation of spatial learning and memory testing was
performed in the partially baited eight-arm maze. Our study
revealed markedly impaired spatial learning skills and
memory deficits in rats after EtOH treatment, which is fully
in line with others (Irle and Markowitsch, 1983; Arendt et
al., 1988; Beracochea et al., 1992; Lukoyanov et al., 2003).
Three weeks after a 5-day training period, long-term mem-
ory was assessed in the retention test, and performance by
EtOH-treated animals was significantly poorer than in con-
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166160trols. It needs to be noted that animals were not withdrawn
from ethanol during the whole testing, but had still access
to ethanol ad libitum. Thus, as rats were habituated for 12
months for EtOH exposure, we can exclude any acute
effects of EtOH on the spatial memory testing during the
maze.
Our data obtained during the retention test show a
significant increase in working memory errors but also in
reference memory errors, as well as in the number of visits
in EtOH-treated rats, thus pointing to a decreased long-
term memory. The mechanism of EtOH-induced impair-
ment of cognitive function is not well understood. However,
it has been reported that EtOH interacts with various signal
transduction cascades (Ku et al., 2007; Aroor and Shukla,
2004), ion channels (Allgaier, 2002; Crews et al., 1996),
econd messengers (Deng and Deitrich, 2007), neu-
otransmitters (Foddai et al., 2004; Jamal et al., 2007), and
heir receptors (Diamond and Messing, 1994).
It is well established that EtOH impairs the cholinergic
Fig. 3. Effect of long-term (12 months) ethanol (EtOH) treatment on
controls (A) and EtOH-treated rats (B,C) was immunohistochemically v
is shown in (C, D). The number of anti-rat IgG-positive spots in the corte
Values are expressed as meanSEM. Values in parenthesis give th
ANOVA with a Fisher LSD post hoc test. * P0.05. Scale bar A800ystem, which is closely associated with learning andmemory (McKinney, 2005; Olton, 1983; Kentroti and Ver-
nadakis, 1996; Costa and Guizzetti, 1999; Jamal et al.,
009; Casamenti et al., 1982; Arendt et al., 1988; Arendt,
994). Cholinergic neurons of the basal forebrain nbM are
ost vulnerable to age-related neurodegeneration (Sassin
t al., 2000), and a significant reduction in cholinergic
asal forebrain neurons has been reported for AD (Mesu-
am, 2010). In order to test the effect of EtOH treatment on
he cholinergic system, we investigated the ACh-synthe-
izing enzyme ChAT and the NGF receptor p75NTR on
cholinergic neurons in the nbM; both serve as well-known
markers for cholinergic neurons (Oda, 1999). Our data reveal
a markedly decreased number of ChAT- and p75 NTR-
positive cholinergic neurons in the nbM. This was accom-
panied by decreased ACh levels in the cortex, and it is well
established that a loss of the neurotransmitter ACh directly
correlates with cognitive decline in AD (Mufson et al.,
2005; Mesulam, 2010; Bowen et al., 1976). It has been
reported that approximately 95% of p75NTR-positive neu-
G staining in the cortex. Blood–brain barrier leakage in the cortex of
with anti-rat IgG staining. A magnification of anti-rat IgG-positive spots
arkedly enhanced in EtOH-treated animals as compared with controls.
r of experiments. Statistical analysis was performed with a one-way
B) and 360 m (C).anti-rat Ig
isualized
x was mrons co-localize with ChAT-positive neurons in the nbM
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166 161(Mufson et al., 2003). Thus, our data clearly show that a
small population of ChAT- or p75NTR-positive nbM neurons
as reduced after chronic EtOH treatment, and it is likely
hat these neurons degenerated because both markers
eclined at the same time.
NGF and its high-(trkA) and low-affinity (p75NTR) re-
ceptors play an important role in survival of cholinergic
basal forebrain neurons. In AD a loss of NGF in the basal
forebrain and high NGF levels in the cortex have been
reported (Mufson et al., 2008). NGF accumulates in target
regions, such as the cortex and hippocampus, because of
damage of the retrograde transport mechanism (Schin-
dowski et al., 2008). In addition, it has been reported that
NGF is able to counteract EtOH-induced deficits in the
cholinergic system (Lukoyanov et al., 2003; Aloe and Ti-
rassa, 1992; Paula-Barbosa et al., 2001) as well as in
cultured cerebral cortical (Mooney and Miller, 2007), hip-
pocampal (Webb et al., 1997), and cerebellar neurons
(Luo et al., 1997). Our data show that after 12 months of
EtOH treatment NGF levels in the cortex did not differ from
those of controls, which is in line with others (Baek et al.,
1994). It seems possible that NGF may be increased at
earlier time points of EtOH treatment to counteract cholin-
ergic cell loss, as suggested by Nakano et al. (1996).
It is well known that EtOH is a cerebrovascular risk
factor and may also contribute to impairment of the cho-
linergic system by inducing oxidative stress (Deng and
Deitrich, 2007; Toda and Ayajiki, 2010; Das and Vasude-
van, 2007; Haorah et al., 2005; Nordmann et al., 1990).
Indeed, it has been reported that EtOH causes BBB dis-
Fig. 4. Effect of long-term (12 months) ethanol (EtOH) treatment on c
nimals were immunohistochemically stained for the microglial marker
mmunoreactivity in the cortex of EtOH-treated rats. OX-42 density o
hemistry. Cortical OX-42 density was not affected by EtOH treatme
umber of experiments. Statistical analysis was performed with Studeruption with enhanced monocyte migration into the brain n(Haorah et al., 2005). In the present study macrovascular
structures in the cortex were stained for the well-estab-
lished vessel markers laminin and RECA-1, but no differ-
ences were seen between EtOH-treated rats and controls.
However, when brains were stained for anti-rat IgG a large
number of IgG-positive spots was found in EtOH-treated
rats as compared with controls. These results show in-
creased influx of rat IgG into the brain, indicating BBB
breakdown, similar to our report on results following hyper-
homocysteinemia (Pirchl et al., 2010) or hypercholesterol-
emia (Ullrich et al., 2010) in vivo in rats.
As an additional indication for a BBB breakdown we
easured tPA, which is a serin protease that is predomi-
antly found in blood and plays a role in thrombolysis. We
ound that tPA levels were markedly increased in the cor-
ex, suggesting influx from blood after BBB breakdown.
his agrees with others showing an increase in tPA levels
fter chronic EtOH treatment followed by EtOH withdrawal
Skrzypiec et al., 2009). Interestingly, tPA is also impli-
ated in the development of fetal alcohol syndrome in
ice, and tPA-deficient mice were protected from EtOH-
nduced neurotoxicity (Noel et al., 2011). However, tPA is
lso expressed by neurons and astrocytes and changes
ay also reflect changes in the expression/activity of tPA
n these cells and not in BBB permeability. tPA activates
lasminogen into plasmin, which in turn degrades laminin
Benarroch, 2007). Indeed, EtOH-induced tPA upregula-
ion increases laminin degradation and reduces levels of
aminin in the hippocampus (Skrzypiec et al., 2009). Such
tPA-induced degradation of laminin may be involved in
icroglia Iba-1 and OX-42 stainings. Control (A) and EtOH-treated (B)
Quantitative analysis revealed a significant enhancement of Iba-1-like
(D) and EtOH-treated animals (E) was visualized by immunohisto-
lues are expressed as meanSEM. Values in parenthesis give the
t, P0.05; ns, not significant. Scale bar in A200 m (A, B, D, E).ortical m
Iba-1. (C)
f controlseuronal plasticity including learning and memory (Laifen-
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166162feld et al., 2005). In our study we measured laminin as a
vascular marker, but could not detect any changes in its
vascular structure. However, laminin is also expressed by
astrocytes, and we cannot exclude that the increase in tPA
is accompanied by a decrease in astrocyte-released
laminin.
Inflammation and microglia activation is a well-known
pathology in AD as well as in EtOH-induced neurodegen-
eration (Kaur et al., 1995), prompting secretion of different
pro-inflammatory mediators, such as TNF- or MCP-1 (Qin
t al., 2007, 2008). Our data demonstrate that long-term
tOH treatment significantly enhanced cortical MCP-1 lev-
ls, whereas levels of other inflammatory markers, such as
L-1, MIP-2, or TNF-, were not affected by EtOH treat-
ent. The cytokine MCP-1 has been linked to inflamma-
ion, where it mediates migration and activation of micro-
lia (McManus et al., 2000), most likely by raising the
ermeability of the BBB (Yamamoto et al., 2005; Stama-
ovic et al., 2003, 2005). In addition, it has been suggested
hat MCP-1 takes part in EtOH drinking behavior (Blednov
t al., 2005). In fact, MCP-1 knockout mice demonstrate
arkedly reduced EtOH consumption and preference
Blednov et al., 2005). Furthermore, the level of MCP-1 in
rains of EtOH-dependent individuals is significantly
igher than in non-drinkers, which was investigated in
ostmortem human brain studies (He and Crews, 2008).
nhancement of MCP-1 without changes in other cyto-
ines such as IL-1, MIP-2, or TNF- was also reported by
thers (Little et al., 2002), suggesting that MCP-1 may take
art in a signaling cascade induced by EtOH treatment that
iffers from its role as a pro-inflammatory cytokine. MCP-1
n the brain is secreted by activated microglia (Kaul et al.,
001), and indeed our data show microglial activation in
he cortex of EtOH-treated animals. Microglia are activated
n inflamed brains (Kaur et al., 1995) and in the present
tudy microglia reactivity was investigated by the well-
stablished surface markers Iba-1 and OX-42, which label
esting as well as activated microglia. The antibody OX-42
ecognizes CD11b that serves as a receptor for comple-
ent (Wagner et al., 2011). We were able to show upregu-
ation of Iba-1, but not OX-42, which indicates that the
ctivation stages of microglia may reflect a distinct expres-
ion pattern of the surface markers (Ji et al., 2007).
We recently well established and characterized the
ffects of 5 months of hypercholesterolemia in rats in vivo
Ullrich et al., 2010). We showed that a 5% cholesterol diet
arkedly reduced spatial learning, cholinergic neurons,
nduced inflammation, and BBB leakage in the cortex (Ull-
ich et al., 2010). Interestingly, chronic EtOH or cholesterol
reatment for 12 months had similar effects in vivo, al-
hough not as pronounced as the 5-month cholesterol
ffects. Interestingly, long-term treatment of cholesterol did
ot result in dramatic inflammation and changes were not
s pronounced, possibly because of adaptive and com-
150150 m2 grids. Values are expressed as meanSEM. Values in
arenthesis give the number of experiments. Statistical analysis was
erformed with Student’s t-test. ns, not significant. Scale bar in A800Fig. 5. Vascular structures in cortex after EtOH treatment for 12 mon.
Brain sections were immunohistochemically stained for laminin (A) or
RECA-1 (B). The inserts in (A, B) show a magnification. Note that in (A)
laminin staining is also visible outside the blood vessels, possibly
pointing to astrocytic staining. (C) Vascular structures were not seen to
be affected by EtOH treatment, namely measurement of neither vas-
cular crossings nor optical density (OD) showed an effect. Vascularm (A, B), and 1100 m (inserts).
PC
n
d
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D. Ehrlich et al. / Neuroscience 205 (2012) 154–166 163pensatory mechanisms. This is in agreement with Pirchl et
al. (2010), who reported that short-term (5 months) treat-
ment with the vascular risk factor homocysteine had more
severe effects than did long-term (15 months) homocys-
teine treatment. In future studies it will be interesting to
explore whether short-term EtOH treatment induces stron-
ger damage than long-term treatment.
The present study also aimed to observe a combined
effect of EtOH and cholesterol on cognition, inflammation,
cholinergic neurons, and vascular structures. It was inter-
esting to see that the combination of EtOH and cholesterol
did not dramatically affect the changes in spatial memory,
cholinergic neurons, inflammation, and vascularity. In fact,
our data show that EtOH rather counteracted some of the
cholesterol-induced effects: it reduced weight, plasma cho-
lesterol levels, and cortical A(1–40) and A(1–42) content.
The A-peptides are processed by secretases from APP
and are deposited in the brain (neuritic plaques) or in
Table 3. Effects of long-term (12 mon) ethanol (EtOH) and cholestero
Controls EtOH
Weight 100  4 (12) 89  2 (12)
Maze
Session 5 100  4 (12) 51  6 (12)
Retention 100  5 (12) 49  3 (12)
WME 100  25 (12) 252  36 (12)
RME 100  25 (12) 243  32 (12)
RWME 100  77 (12) 700  226 (12)
Visits 100  6 (12) 136  11 (12)
Duration 100  9 (12) 111  4 (12)
Arm latency 100  12 (12) 100  13 (12)
lasma
EtOH below DL (6) 2500  1040 (6)
Cholesterol 100  14 (6) 68  8 (6)
tPA 100  13 (3) 106  30 (3)
ortex
Acetylcholine 100  21 (6) 42  21 (6)
NGF 100  7 (6) 92  17 (6)
tPA 100  9 (6) 155  10 (6)
IgG spots 100  29 (6) 323  55 (6)
-amyloid(1–40) 100  7 (4) 106  12 (4)
-amyloid(1–42) 100  2 (4) 98  13 (4)
Interleukin-1 100  8 (6) 100  36 (3)
MIP-2 100  25 (6) 49  16 (3)
TNF- 100  15 (6) 73  19 (3)
MCP-1 100  7 (6) 143  21 (3)
RECA 1[OD] 100  10 (6) 106  8 (6)
RECA-1 [cross] 100  5 (6) 96  2 (6)
Laminin [OD] 100  3 (6) 95  8 (6)
Laminin [cross] 100  9 (6) 74  10 (6)
bM
ChATneurons 100  6 (6) 83  8 (6)
Sprague–Dawley rats were administered normal food and drinking w
enriched diet (Chol) or a combination of 20% EtOH v/v in drinking wate
as meanSEM% of control. Absolute raw values of controls see Tab
Fisher LSD post hoc test. p1 compares EtOH and controls; p2 choles
** P0.01; *** P0.001). Abbreviations: WME, working memory error
etection limit; NGF, nerve growth factor; tPA, tissue plasminogen a
actor-alpha; MIP-1, monocyte-chemotactic protein-1; OD, optical dens
ucleus basalis of Meynert.vessels (angiopathy) of AD patients (Hardy and Selkoe,2002). The longer A(1–42) oligomer is the predominant
form found in amyloid brain plaques (Querfurth and
LaFerla, 2010). Accumulation of A leads to damage of
synapses and an abnormal phosphorylation of tau (Lacor
et al., 2007). Interestingly, it has recently been reported
that EtOH protected against A-induced synapse damage
in cultured neurons (Bate and Williams, 2011). This is in
line with our present study where a protective effect of
EtOH-induced beta-amyloid has been suggested.
In the maze EtOH enhanced the number of visits and
thus increased RME and WRME, suggesting increased
activity as compared with the cholesterol group, possibly
because of reduced weight. The effect of EtOH on choles-
terol-induced vascular changes is divergent, because it en-
hanced RECA-1 optical density but decreased laminin-posi-
tive crossings. This may indicate a loss of vessel integrity and
enhanced vascular shaping. Some of the effects of EtOH
may also be modulated by its antiproliferative effect on as-
treatment
Chol p2 EtOHChol p3 p4
112  4 (12) * 96  3 (12) ns **
57 6 (9) ** 55  3 (12) ns ns
51 6 (9) ** 55  4 (12) ns ns
173  48 (9) ns 267  41 (12) ns ns
133  31 (9) ns 205  18 (12) ns *
200  71 (9) ns 500  107 (12) ns *
97  13 (9) ns 132  7 (12) ns **
113  9 (9) ns 99  8 (12) ns ns
181  50 (9) ns 84  16 (12) ns ns
89  7 (3) ns 140  20 (6) * **
149  29 (3) *** 65  16 (5) ns *
163  21 (3) * 84  40 (3) ns ns
47 11 (3) * 60  19 (6) ns ns
133  23 (3) ns 107  14 (6) ns ns
110  10 (3) ns 132  10 (6) ns ns
438  85 (6) ** 329  68 (6) ns ns
207  8 (3) * 60  4 (6) ** ***
224  79 (3) ns 96  2 (6) ns *
124  16 (6) ns 108  12 (6) ns ns
108  25 (6) ns 108  25 (6) ns ns
81 12 (6) ns 69  15 (6) ns ns
144  22 (6) * 109  7 (6) ns ns
114  6 (6) ns 133  6 (6) * *
94  2 (6) ns 89  4 (6) ns ns
79  3 (6) ** 90  8 (6) ns ns
120  3 (6) * 77  11 (6) ns **
82  4 (6) * 98  7 (6) ns ns
ntrols) or 20% v/v EtOH in drinking water (EtOH) or a 5% cholesterol-
holesterol-enriched diet (EtOHChol) for 12 mon. All values are given
2. Statistical analysis was performed with a one-way ANOVA with a
controls; p3 mixed and EtOH; p4 mixed and cholesterol (* P0.05;
ference memory error; RWME, reference working memory error; DL,
MIP-2, macrophage inflammatory protein-2; TNF-, tumor necrosis
, choline-acetyltransferase; cross, crossings; ns, not significant; nbM,l (Chol)
p1
*
***
***
**
**
*
*
ns
ns
***
ns
ns
*
ns
***
*
ns
ns
ns
ns
ns
*
ns
ns
ns
ns
ns
ater (co
r and a c
les 1 and
terol and
; RME, re
ctivator;trocytes (Costa et al., 2004) or maintenance of calcium
D. Ehrlich et al. / Neuroscience 205 (2012) 154–166164homeostasis (Catlin et al., 1999). Our data also show that
cholesterol did not markedly affect the EtOH-induced
changes. There was a prominent reduction in plasma
EtOH induced by cholesterol. This may indicate that cho-
lesterol modulates the absorption of EtOH into the blood.
Indeed, retention of EtOH in the stomach is prolonged after
cholesterol-rich nutrition (Gentry, 2000). In addition, cho-
lesterol decreased the cortical A(1–40), but not A(1–42)
levels, and enhanced RECA-1 optical density, which may
point to an effect on the vascular system and a possibly
altered A(1–40) clearance at the BBB.
In summary, long-term EtOH or cholesterol treatment
(12 months) markedly impaired the cholinergic nbM neu-
rons, reduced spatial learning and induced cortical BBB
leakage accompanied by partly increased inflammation.
The combined treatment of rats with EtOH and cholesterol
for 12 months did not potentiate treatment with either EtOH
or cholesterol alone, but instead counteracted some of the
cholesterol- or EtOH-associated effects. In conclusion, the
vascular risk factor EtOH may markedly contribute to some
pathologies that are seen in, for example, vascular demen-
tia but not in AD.
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